We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology

TP53 Multihit Does Not Fully Erase the Prognostic Advantage of Isolated del(5q) in Myelodysplastic Neoplasms

MedXY Editorial Team•May 9, 2026•Hematology-Oncology
del(5q)MDSprognosisTP53 multihit

Highlights

In this retrospective analysis, patients with myelodysplastic neoplasms (MDS) with isolated del(5q) and TP53 multihit alterations had markedly better overall survival and slower acute myeloid leukemia (AML) progression than patients with other low-blast TP53-multihit MDS.

The reported median overall survival was 70.2 months for MDS-del(5q) TP53 multihit versus 13.9 months for low-blast MDS TP53 multihit without isolated del(5q), with corresponding times to AML progression of 31.9 versus 7.2 months.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Molecular Stratification of Early-Stage Vulvar Squamous Cell Carcinoma: Prognostic Impact of HPV and TP53 StatusThis study highlights how HPV and TP53 molecular subtyping in stage I vulvar squamous cell carcinoma delineates survival outcomes and recurrence risks, supporting its role in personalized management strategies.Sep 19, 2026Cardiac Sarcoidosis: Nationwide Insights into Diagnosis, Management, and Outcomes from the MYSTICS RegistryThe MYSTICS Registry provides robust data on cardiac sarcoidosis, highlighting diagnostic challenges, treatment patterns, and prognostic differences among phenotypes, emphasizing tailored management strategies to improve patient outcomes.Sep 17, 2026Optimizing GVHD Prophylaxis after Reduced-Intensity Matched Donor Transplantation in AML and MDS: Insights from PTCy and ATG StrategiesA large registry analysis supports post-transplant cyclophosphamide (PTCy) as an effective alternative to anti-thymocyte globulin (ATG) for preventing graft-versus-host disease (GVHD) in reduced-intensity conditioning matched donor peripherSep 17, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Synergistic Impact of Age and Nerve Degeneration on Bell’s Palsy Recovery: Clinical Implications
Older adults with severe nerve impairment in Bell’s palsy experience markedly poorer recovery, highlighting the critical role of early, aggressive intervention.
Sep 13, 2026
Enhancing Prognosis in Bell Palsy: Electrodiagnostic Testing Beyond House-Brackmann GradeElectrodiagnostic tests, notably electroneuronography and electromyography, significantly improve prognosis prediction for Bell palsy recovery, including patients with moderate paralysis (H-B grade IV). These findings support broader use toSep 13, 2026
Decoding CPEB3-Regulated Alternative Polyadenylation: A New Genetic Lens on Hepatocellular Carcinoma PrognosisThis article explores how genetic variants affect CPEB3-mediated alternative polyadenylation in hepatocellular carcinoma, revealing potential prognostic markers and therapeutic targets to improve patient survival.Sep 5, 2026